GABA System in Schizophrenia and Mood Disorders: A Mini Review on Third-Generation Imaging Studies

Third-generation neuroimaging research has been enriched by advances in magnetic resonance spectroscopy (MRS) measuring the concentration of important neurotrasmitters, such as the inhibitory amino acid GABA. Here, we performed a systematic mini-review on brain MRS studies measuring GABA concentration in patients affected by schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD). We wondered whether multimodal investigations could overcome intrinsic technical limits of MRS giving a broader view of mental disorders pathogenesis. In SZ, unimodal studies gave mixed results, as increased, decreased, or unaltered GABA levels were reported depending on region, disease phase, and treatment. Conversely, multimodal results showed reduced level of glutamate, but not of GABA, in patients mirrored by in vitro biochemical findings revealing hippocampal reduction in glutamate signaling in SZ, and no deficits in GABA synthesis. Moreover, a mouse model confirmed the unique pathological characteristic of glutamate function in SZ. Unimodal studies in BD revealed again, inconsistent results, while no multimodal investigations including MRS on GABA exist. In MDD, unimodal studies could not differentiate patients from controls nor characterize high-risk subjects and remitted patients. However, a multimodal study combining functional magnetic resonance imaging and MRS revealed that cingulate cortex activity is related to glutamate, N-acetylaspartate levels and anhedonia in patients, and to GABA concentration in healthy subjects, improving the distinction between MDD and physiology. Overall, our results show that unimodal studies do not indicate GABA as a biomarker for the psychiatric disorders considered. Conversely, multimodal studies can widen the understanding of the link between psychopathology, genetics, neuroanatomy, and functional–biochemical brain activity in mental disorders. Although scarce, multimodal approaches seem promising for moving from GABA MRS unimodal-descriptive to causal level, and for integrating GABA results into a more comprehensive interpretation of mental disorder pathophysiology.

[1]  J. Bustillo,et al.  Medial-frontal cortex hypometabolism in chronic phencyclidine exposed rats assessed by high resolution magic angle spin 11.7T proton magnetic resonance spectroscopy , 2012, Neurochemistry International.

[2]  P. Cowen,et al.  Elevated cortical glutamate in young people at increased familial risk of depression. , 2011, The international journal of neuropsychopharmacology.

[3]  T. Ohmori,et al.  GABA concentration in schizophrenia patients and the effects of antipsychotic medication: A proton magnetic resonance spectroscopy study , 2010, Schizophrenia Research.

[4]  J. Coyle The GABA-glutamate connection in schizophrenia: which is the proximate cause? , 2004, Biochemical pharmacology.

[5]  Maja Jazvinšćak Jembrek,et al.  GABA Receptors: Pharmacological Potential and Pitfalls. , 2015, Current pharmaceutical design.

[6]  Georg Northoff,et al.  Associations of regional GABA and glutamate with intrinsic and extrinsic neural activity in humans—A review of multimodal imaging studies , 2014, Neuroscience & Biobehavioral Reviews.

[7]  A. O'Neil,et al.  Statin and Aspirin Use and the Risk of Mood Disorders among Men , 2016, The international journal of neuropsychopharmacology.

[8]  P. Cowen,et al.  Cortical glutathione levels in young people with bipolar disorder: a pilot study using magnetic resonance spectroscopy , 2013, Psychopharmacology.

[9]  René S. Kahn,et al.  GABA and glutamate in schizophrenia: A 7 T 1H-MRS study , 2014, NeuroImage: Clinical.

[10]  Gregor Hasler,et al.  Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. , 2007, Archives of general psychiatry.

[11]  D. Frost,et al.  Olanzapine antipsychotic treatment of adolescent rats causes long term changes in glutamate and GABA levels in the nucleus accumbens , 2015, Schizophrenia Research.

[12]  Peter Kochunov,et al.  Medial Frontal GABA is Lower in Older Schizophrenia: A MEGA-PRESS with Macromolecule Suppression Study , 2015, Molecular Psychiatry.

[13]  Peter Boesiger,et al.  The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression. , 2009, Archives of general psychiatry.

[14]  J. Coyle,et al.  In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnormalities in the serine racemase knockout mouse model of schizophrenia , 2015, Neurobiology of Disease.

[15]  C. John Evans,et al.  Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA , 2014, NeuroImage.

[16]  A. Egerton,et al.  The glutamate hypothesis of schizophrenia: neuroimaging and drug development. , 2012, Current pharmaceutical biotechnology.

[17]  P. Renshaw,et al.  Brain GABA levels in patients with bipolar disorder , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[18]  Marzena Wylezinska,et al.  Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. , 2008, The international journal of neuropsychopharmacology.

[19]  H. Lane,et al.  Assessing and treating cognitive impairment in schizophrenia: current and future. , 2014, Current pharmaceutical design.

[20]  R. Edden,et al.  Gannet: A batch‐processing tool for the quantitative analysis of gamma‐aminobutyric acid–edited MR spectroscopy spectra , 2014, Journal of magnetic resonance imaging : JMRI.

[21]  Sylvain Williams,et al.  Gamma oscillations and schizophrenia. , 2010, Journal of psychiatry & neuroscience : JPN.

[22]  Mark Slifstein,et al.  Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. , 2012, Archives of general psychiatry.

[23]  R. Yoshimura,et al.  No alterations of brain GABA after 6months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  I. Tso,et al.  GABA abnormalities in schizophrenia: A methodological review of in vivo studies , 2015, Schizophrenia Research.

[25]  D. Auer,et al.  In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T. , 2014, Schizophrenia bulletin.

[26]  Derek K. Jones,et al.  Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans , 2009, Proceedings of the National Academy of Sciences.

[27]  R. Edden,et al.  In vivo magnetic resonance spectroscopy of GABA: a methodological review. , 2012, Progress in nuclear magnetic resonance spectroscopy.

[28]  P. Renshaw,et al.  Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. , 2013, Bipolar disorders.

[29]  S. A. Wijtenburg,et al.  In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: Application to schizophrenia , 2015, Neuroscience & Biobehavioral Reviews.

[30]  R. Hari,et al.  The brain in time: insights from neuromagnetic recordings , 2010, Annals of the New York Academy of Sciences.

[31]  P. Matthews,et al.  Reduction in Occipital Cortex γ-Aminobutyric Acid Concentrations in Medication-Free Recovered Unipolar Depressed and Bipolar Subjects , 2007, Biological Psychiatry.

[32]  Michael M. Halassa,et al.  The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia , 2015, Schizophrenia Research.

[33]  J. Bustillo Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update , 2013, Dialogues in clinical neuroscience.

[34]  Sarah H. Lisanby,et al.  Neuroimage: Clinical Gaba Level, Gamma Oscillation, and Working Memory Performance in Schizophrenia , 2022 .

[35]  A. Hunter,et al.  Rhythms and blues: modulation of oscillatory synchrony and the mechanism of action of antidepressant treatments , 2015, Annals of the New York Academy of Sciences.

[36]  C. Tamminga The neurobiology of cognition in schizophrenia. , 2006, The Journal of clinical psychiatry.

[37]  Suresh D. Muthukumaraswamy,et al.  Marked Reductions in Visual Evoked Responses But Not γ-Aminobutyric Acid Concentrations or γ-Band Measures in Remitted Depression , 2013, Biological Psychiatry.

[38]  Etienne Sibille,et al.  Why Are Cortical GABA Neurons Relevant to Internal Focus in Depression? A cross-level model linking cellular, biochemical, and neural network findings , 2014, Molecular Psychiatry.

[39]  S. A. Wijtenburg,et al.  In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. , 2013, Schizophrenia bulletin.

[40]  W. Drevets,et al.  Associations between prefrontal γ-aminobutyric acid concentration and the tryptophan hydroxylase isoform 2 gene, a panic disorder risk allele in women. , 2013, The international journal of neuropsychopharmacology.

[41]  Dost Öngür,et al.  Elevated Gamma-Aminobutyric Acid Levels in Chronic Schizophrenia , 2010, Biological Psychiatry.

[42]  Dennis S. Charney,et al.  Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder , 2009, Biological Psychiatry.

[43]  S. Kéri,et al.  Perceptual and cognitive effects of antipsychotics in first-episode schizophrenia: The potential impact of GABA concentration in the visual cortex , 2013, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[44]  P. Fitzgerald,et al.  The Relationship Between Cortical Inhibition, Antipsychotic Treatment, and the Symptoms of Schizophrenia , 2009, Biological Psychiatry.

[45]  M. Buonocore,et al.  MR spectroscopic studies of the brain in psychiatric disorders. , 2012, Current topics in behavioral neurosciences.

[46]  J J Bartko,et al.  Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia , 2014, Molecular Psychiatry.

[47]  Gregor Hasler,et al.  Normal Prefrontal Gamma-Aminobutyric Acid Levels in Remitted Depressed Subjects Determined by Proton Magnetic Resonance Spectroscopy , 2005, Biological Psychiatry.

[48]  Benjamin A. Ely,et al.  Anterior cingulate cortex γ-aminobutyric acid in depressed adolescents: relationship to anhedonia. , 2012, Archives of general psychiatry.

[49]  A. Graff-Guerrero,et al.  Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy , 2015, The international journal of neuropsychopharmacology.

[50]  R. Elul The genesis of the EEG. , 1971, International review of neurobiology.

[51]  N. Logothetis What we can do and what we cannot do with fMRI , 2008, Nature.

[52]  G. Northoff,et al.  Discovering imaging endophenotypes for major depression , 2011, Molecular Psychiatry.

[53]  GABA circuitry, cells and molecular regulation in schizophrenia: Life in the graveyard , 2015, Schizophrenia Research.

[54]  Jamie Near,et al.  Neurochemistry of major depression: a study using magnetic resonance spectroscopy , 2014, Psychopharmacology.

[55]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[56]  G. Ende Proton Magnetic Resonance Spectroscopy: Relevance of Glutamate and GABA to Neuropsychology , 2015, Neuropsychology Review.

[57]  Jong H. Yoon,et al.  GABA Concentration Is Reduced in Visual Cortex in Schizophrenia and Correlates with Orientation-Specific Surround Suppression , 2010, The Journal of Neuroscience.

[58]  A. Henning,et al.  Anterior cingulate Glutamate–Glutamine cycle metabolites are altered in euthymic bipolar I disorder , 2015, European Neuropsychopharmacology.

[59]  M. Buonocore,et al.  Magnetic resonance spectroscopy of the brain: a review of physical principles and technical methods , 2015, Reviews in the neurosciences.